CSF2 and rheumatoid arthritis: MOR103, an IgG1 anti‐GM‐CSF 110 tested in a randomized phase Ib/IIa, double‐blind, placebo‐controlled trial in RA patients, showed a better clinical response [in terms of disease activity score in 28 joints (DAS28)] than placebo‐treated patients in a dose‐dependent manner, along with a favourable safety profile 111.Thus, results to date suggest that targeting the GM‐CSF pathway could be a good treatment option in RA, particularly for patients not responding to TNF blockers.